124 related articles for article (PubMed ID: 35780705)
1. Trends in disagreement with outside genitourinary pathology diagnoses at an academic center.
Taylor C; Puzyrenko A; Iczkowski KA
Pathol Res Pract; 2022 Aug; 236():153997. PubMed ID: 35780705
[TBL] [Abstract][Full Text] [Related]
2. Second opinion pathologic review in the management of prostate cancer.
Chen B; Talwar R; Schwartz LE; Terlecki RP; Guzzo TJ; Kovell RC
Can J Urol; 2021 Feb; 28(1):10530-10535. PubMed ID: 33625343
[TBL] [Abstract][Full Text] [Related]
3. Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
Wissing M; Brimo F; Chevalier S; Scarlata E; McKercher G; O'Flaherty A; Aprikian S; Thibodeau V; Saad F; Carmel M; Lacombe L; Têtu B; Ekindi-Ndongo N; Latour M; Trudel D; Aprikian A
BJU Int; 2019 Apr; 123(4):624-631. PubMed ID: 30113732
[TBL] [Abstract][Full Text] [Related]
4. Gleason score 5 + 3 = 8 (grade group 4) prostate cancer-a rare occurrence with contemporary grading.
Kryvenko ON; Williamson SR; Schwartz LE; Epstein JI
Hum Pathol; 2020 Mar; 97():40-51. PubMed ID: 31923450
[TBL] [Abstract][Full Text] [Related]
5. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
6. Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy.
Diolombi ML; Epstein JI
BJU Int; 2017 Jun; 119(6):872-878. PubMed ID: 27496532
[TBL] [Abstract][Full Text] [Related]
7. Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer.
Czaja RC; Tarima S; Wu R; Palagnmonthip W; Iczkowski KA
Ann Diagn Pathol; 2021 Jun; 52():151725. PubMed ID: 33610958
[TBL] [Abstract][Full Text] [Related]
8. Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance.
Audenet F; Rozet F; Resche-Rigon M; Bernard R; Ingels A; Prapotnich D; Sanchez-Salas R; Galiano M; Barret E; Cathelineau X
Clin Genitourin Cancer; 2017 Dec; 15(6):e907-e913. PubMed ID: 28522288
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic significance of stromal changes in biopsies of prostate adenocarcinoma.
Dzaparidze G; Kazachonok D; Gvozdkov A; Taelma H; Laht K; Minajeva A
Pathol Res Pract; 2021 Jun; 222():153436. PubMed ID: 33857855
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens.
Nagpal K; Foote D; Tan F; Liu Y; Chen PC; Steiner DF; Manoj N; Olson N; Smith JL; Mohtashamian A; Peterson B; Amin MB; Evans AJ; Sweet JW; Cheung C; van der Kwast T; Sangoi AR; Zhou M; Allan R; Humphrey PA; Hipp JD; Gadepalli K; Corrado GS; Peng LH; Stumpe MC; Mermel CH
JAMA Oncol; 2020 Sep; 6(9):1372-1380. PubMed ID: 32701148
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution.
Okubo Y; Yamamoto Y; Sato S; Yoshioka E; Suzuki M; Washimi K; Osaka K; Suzuki T; Yokose T; Kishida T; Miyagi Y
Virchows Arch; 2022 May; 480(5):979-987. PubMed ID: 35015130
[TBL] [Abstract][Full Text] [Related]
12. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
[TBL] [Abstract][Full Text] [Related]
13. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
[TBL] [Abstract][Full Text] [Related]
14. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.
Ström P; Kartasalo K; Olsson H; Solorzano L; Delahunt B; Berney DM; Bostwick DG; Evans AJ; Grignon DJ; Humphrey PA; Iczkowski KA; Kench JG; Kristiansen G; van der Kwast TH; Leite KRM; McKenney JK; Oxley J; Pan CC; Samaratunga H; Srigley JR; Takahashi H; Tsuzuki T; Varma M; Zhou M; Lindberg J; Lindskog C; Ruusuvuori P; Wählby C; Grönberg H; Rantalainen M; Egevad L; Eklund M
Lancet Oncol; 2020 Feb; 21(2):222-232. PubMed ID: 31926806
[TBL] [Abstract][Full Text] [Related]
15. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Agostino J; Macura KJ; Carter HB; Schaeffer EM; Partin AW; Sokoll LJ; Ross AE
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):228-233. PubMed ID: 28117387
[TBL] [Abstract][Full Text] [Related]
16. The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.
Barqawi AB; Turcanu R; Gamito EJ; Lucia SM; O'Donnell CI; Crawford ED; La Rosa DD; La Rosa FG
Int J Clin Exp Pathol; 2011 Jun; 4(5):468-75. PubMed ID: 21738818
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
Waisman Malaret AJ; Chang P; Zhu K; Zheng Y; Newcomb LF; Liu M; McKenney JK; Brooks JD; Carroll P; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Lin DW; Wagner AA
J Urol; 2022 Apr; 207(4):805-813. PubMed ID: 34854745
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Significance of Perineural Invasion by Prostate Cancer on Needle Core Biopsy: Involvement of Single Versus Multiple Sextant Sites.
Bell PD; Teramoto Y; Gurung PMS; Numbere N; Yang Z; Miyamoto H
Arch Pathol Lab Med; 2022 Oct; 146(10):1252-1257. PubMed ID: 35020791
[TBL] [Abstract][Full Text] [Related]
19. Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis.
Leong JY; Herrera-Caceres JO; Goldberg H; Tham E; Teplitsky S; Gomella LG; Trabulsi EJ; Lallas CD; Fleshner NE; Tilki D; Chandrasekar T
Urology; 2020 Mar; 137():102-107. PubMed ID: 31705947
[TBL] [Abstract][Full Text] [Related]
20. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
